Bisphosphonates For Cancer Patients
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA Patient Case Study: Prostate Cancer ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Prostate Cancer Patient Case Study – Dieter Dieter V.
  • Aged 61 years
  • Manages a department store
  • Coaches his grandson's football team
Medical Profile The clinical question Reasons for ZOMETA How to use ZOMETA References
Page  1 2 3 4 5


NCCN and EAU guidelines support bisphosphonate use in patients like Dieter with prostate cancer


National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU) guidelines state17,18
  • Bisphosphonates may be administered to prevent skeletal complications in patients with hormone-refractory prostate cancer and bone metastases
  • EAU guidelines also state that bisphosphonates may be administered to palliate pain in this patient population

ZOMETA® is proven in clinical trials to delay and reduce SREs in prostate cancer through 24 months16


Achieve maximum efficacy—treat with ZOMETA 4 mg every 3 to 4 weeks


Page  1 2 3 4 5


 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.